布地奈德与异丙托溴铵治疗慢性阻塞性肺疾病的临床效果

Clinical Effect of Budesonide and Ipratropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease

目的研究慢性阻塞性肺疾病患者行布地奈德联合异丙托溴铵治疗的效果。方法数据采集本医院就诊的88例慢性阻塞性肺疾病患者,按照随机数字表法分观察组(布地奈德+异丙托溴铵,n=44)与对照组(常规疗法,n=44),比较两组血清炎性因子、肺功能、治疗效果及不良反应。结果治疗前比较炎症因子、肺功能差异无统计学意义;两组不良反应比较差异无统计学意义,P>0.05;治疗后与对照组比较,观察组血管内皮生长因子(vascular endothelial growth factor,VEGF)、细胞间黏附分子-1(intercellular adhesion molecule-1,ICAM-1)及白细胞介素-13(interleukin-13,IL-13)指标更低;观察组第1 s用力呼气容积(1s forced expiratory volume,FEV1)、用力肺活量(forced vital capacity,FVC)、呼气峰值流速(peak expiratory flow,PEF)及第1 s用力呼气容积/用力肺活量(1 s forced expiratory volume/forced vital capacity,FEV1/FVC)指标更高,P<0.05;观察组总有效率(97.73%)高于对照组(86.36%),χ^(2)=3.8801,P=0.0488<0.05。结论布地奈德+异丙托溴铵治疗慢性阻塞性肺疾病能增强疗效、保证用药可行性,促进患者肺功能恢复。

Objective To study the effect of budesonide and ipratropium bromide in patients with chronic obstructive pulmonary disease.Methods Data collection of 88 patients with COPD in our hospital were divided into observation group(budesonide and ipratropium bromide,n=44)and control group(conventional therapy,n=44)according to the random number table method,comparison of serum inflammatory factors,lung function,treatment effect and adverse reactions between the two groups.Results There was no difference in inflammatory factors and lung function before treatment;there was no difference in the proportion of adverse reactions between the two groups,P>0.05;after treatment,compared with the control group,the observation group showed vascular endothelial growth factor(VEGF),Intercellular adhesion molecule-1(ICAM-1)and interleukin-13(IL-13)indicators were lower;the observation group was forced to expiratory volume at 1 s(1 s forced expiratory volume,FEV1),forced vital capacity(FVC),peak expiratory flow(PEF)and forced expiratory volume/forced vital capacity(1 s forced expiratory volume/forced vital capacity,FEV1/FVC)indicators High,P<0.05;the total effective rate of observation group(97.73%)is higher than that of control group(86.36%),χ^(2)=3.8801,P=0.0488<0.05.Conclusion Budesonide and ipratropium bromide in the treatment of COPD can enhance the curative effect,ensure the feasibility of medication,and promote the recovery of patients'lung function.